Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Preferred Stock Liabilities (2018 - 2021)

X4 Pharmaceuticals (XFOR) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $1.9 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Jun 2021, changed N/A, and an annual FY2018 reading of $4.9 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $1.9 million for Q2 2021 at X4 Pharmaceuticals, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $64.7 million in Q3 2018 and bottomed at $1.9 million in Q1 2021.